PSMD10 AS A SELECTIVE REGULATOR OF MHC CLASS II EXPRESSION IN MULTIPLE MYELOMA

EHA Library, ZUZANNA TRACZ-GASZEWSKA, 4208390

INVESTIGATION ON THE EFFECT AND MOLECULAR MECHANISM OF THE ATP1B4  ON THE RESISTANCE TO PROTEASOME INHIBITORS IN MULTIPLE MYELOMA

EHA Library, Xueming Jia, 4208391

THE NOVEL RETINOID WYC-209 SENSITIZES MULTIPLE MYELOMA TO CARFILZOMIB VIA EPIGENETICALLY UPREGULATING ZMYND8

EHA Library, Bing Chen, 4208392

MDSCS DRIVE T CELL SENESCENCE TO FACILITATE TUMOR GROWTH AND STEM CELL-LIKE PROPERTIES IN MULTIPLE MYELOMA

EHA Library, Lisha Ai, 4208394

ARGINASE INHIBITION ENABLES NEUTROPHIL GRANULOCYTE-DRIVEN HYPERACTIVATION OF T CELLS FROM PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Ann-Katrin Gebel, 4208395

DR4/DR5 AGONISTS SYNERGIZE WITH BH3 MIMETICS VENETOCLAX TO PROMOTE APOPTOSIS IN MULTIPLE MYELOMA

EHA Library, Yiwen Jiang, 4208396

BIODEGRADABLE ALBUMIN-BASED NANOCAPSULES CO-DELIVERING ANGIOSTATIN AND THROMBOSPONDIN-1 INHIBIT PRO-ANGIOGENIC SIGNALING AND PROLIFERATION IN MULTIPLE MYELOMA.

EHA Library, Patrycja Stodolak, 4208399

TURNING IMMUNOSUPPRESSION INTO THERAPY: LIPOSOMAL DEXAMETHASONE WITH ANTI-CD47 IN MULTIPLE MYELOMA

EHA Library, Jelena Lazarevic, 4208403

PREDICTIVE IMMUNE BIOMARKERS OF RESPONSE TO BISPECIFIC ANTIBODIES IN TRIPLE-CLASS REFRACTORY MULTIPLE MYELOMA PATIENTS

EHA Library, Elena Tofacchi, 4208407

BELANTAMAB MAFODOTIN, BORTEZOMIB, AND DEXAMETHASONE VS DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED 4-YEAR RESULTS OF THE PHASE 3 DREAMM-7 TRIAL

EHA Library, Vania Hungria, 4208413

CEVOSTAMAB (FCRH5XCD3 BISPECIFIC ANTIBODY) INDUCES DURABLE RESPONSES IN PATIENTS WITH LATE-LINE RRMM WHO HAVE RECEIVED PRIOR BCMA-TARGETED CAR T-CELL THERAPY: EXPANSION RESULTS FROM THE CAMMA 2 STUDY

EHA Library, Shaji Kumar, 4208416

FIRST INTERIM ANALYSIS OF DOMAIN 1 – TECLISTAMAB (TEC) AND TALQUETAMAB (TAL) OF THE CENTRALIZED PLATFORM FOR FUNCTIONAL HIGH-RISK MULTIPLE MYELOMA ––  ZEPFHR STUDY AMARC 24-01.

EHA Library, Sueh-Li Lim, 4208417

TECLISTAMAB IN RELAPSED/REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A RETROSPECTIVE MULTICENTER STUDY BY THE GERMAN SOCIETY FOR AMYLOID DISEASES

EHA Library, Alexander Carpinteiro, 4208424

IBERDOMIDE PLUS DARATUMUMAB AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) BY RENAL FUNCTION: SUBGROUP ANALYSIS OF THE CC-220-MM-001 TRIAL

EHA Library, Anna Sureda, 4208426

MRD-GUIDED MAINTENANCE THERAPY WITH BELANTAMAB MAFODOTIN AND LENALIDOMIDE AFTER AUTO-HCT IN NEWLY DIAGNOSED MULTIPLE MYELOMA: INTERIM ANALYSIS

EHA Library, Yosra Aljawai, 4208429

SAFETY AND EFFICACY OF APONERMIN-BASED CHEMOTHERAPY AS BRIDGING THERAPY BEFORE CAR-T CELL TREATMENT IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Yi Wang, 4208432

ESTABLISHING FULLY OUTPATIENT CILTACABTAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: FIRST CLINICAL DATA FROM EUROPE

EHA Library, Tim Richardson, 4208433

UPDATED RESULTS FROM RANDOMIZED PHASE II DOSE OPTIMIZATION STUDY OF INOBRODIB (CCS1477), IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, Nisha Joseph, 4208434

IMPACT OF IMMUNOMODULATORY CONTAINING HOLDING THERAPY REGIMENS ON OUTCOMES IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS RECEIVING CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY

EHA Library, Veena Krishnan, 4208435

AGE AND FRAILTY ANALYSES OF TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA IN PHASE 3 MAIA/CEPHEUS TRIALS OF DARATUMUMAB + (BORTEZOMIB)-LENALIDOMIDE-DEXAMETHASONE

EHA Library, Saad Z Usmani, 4208437

A PROSPECTIVE STUDY OF OPTIMIZING THERAPY BASED ON DFLC REDUCTION AT WEEK 1 FOR IMPROVED OUTCOMES IN PATIENTS WITH T(11;14) AMYLOIDOSIS

EHA Library, Yang Liu, 4208438

SAFETY AND EFFICACY OF FIRST-LINE SELINEXOR PLUS BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE (XVRD) IN HIGH RISK NEWLY DIAGNOSED MULTIPLE MYELOMA: A MULTI-CENTER, SINGLE-ARM, PHASE IB/II TRIAL

EHA Library, Zhongjun Xia, 4208443

NEXT-GENERATION FLOW CYTOMETRY-BASED DETECTION OF CIRCULATING PLASMA CELLS PREDICTS CYTOGENETIC HIGH-RISK DISEASE AND DEPTH OF RESPONSE IN NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Neha Singh, 4208446

DEVELOPMENT AND VALIDATION OF A NOVEL SOCIAL FRAILTY–INTEGRATED STAGING SYSTEM FOR PREDICTING SURVIVAL IN MULTIPLE MYELOMA

EHA Library, Kosuke Shima, 4208448

REAL-WORLD EFFECTIVENESS AND SAFETY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PRELIMINARY RESULTS FROM THE PROSPECTIVE, NON-INTERVENTIONAL MAGNETISMM-16 STUDY

EHA Library, Jindriska Lindsay, 4208450

PATTERNS OF MGUS IN MEN AND WOMEN PARTICIPATING IN THE SCREENED POPULATION-BASED ISTOPMM STUDY: EARLIER ONSET OR ACCELERATED M PROTEIN INCREASE IN MEN?

EHA Library, Anna Richardson, 4208451

TRENDS IN HOSPITALIZATION FOR MULTIPLE MYELOMA IN SPAIN (2016–2023): RISING HEALTHCARE BURDEN AND DECLINING IN-HOSPITAL MORTALITY

EHA Library, Ane Brieva Lopez, 4208452

COMMITMENTT-TEC: A GLOBAL REAL-WORLD (RW) STUDY OF TECLISTAMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, Guido Lancman, 4208453

DYNAMICS OF SARCOPENIA PARAMETERS PREDICT SURVIVAL IN OLDER PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Febe Smits, 4208454

MRD-NEGATIVE RESPONSE AFTER VRD INDUCTION, HD-ASCT AND VRD CONSOLIDATION IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: PHASE 2 REMNANT STUDY WITH BROAD INCLUSION CRITERIA

EHA Library, Frida Bugge Askeland, 4208456

MRD–PET DISCORDANCE REVEALS COMPARTMENTALIZED DISEASE IN MULTIPLE MYELOMA: PROGNOSTIC IMPLICATIONS FROM 1138 PAIRED ASSESSMENTS

EHA Library, Max Mendez-Lopez, 4208459

OUTCOMES OF THERAPY AFTER PROGRESSION ON TALQUETAMAB IN PATIENTS WITH HEAVILY PRETREATED RELAPSED REFRACTORY MULTIPLE MYELOMA

EHA Library, Gannon Ray, 4208462

HIGHER INCIDENCE OF SECONDARY EXTRAMEDULLARY DISEASE AFTER ANTI-CD38 THERAPY IN MULTIPLE MYELOMA: A CZECH NATIONAL REGISTRY REAL-WORLD MATCHED STUDY

EHA Library, Martin Stork, 4208463

1Q GAINS DETECTED BY OPTICAL GENOME MAPPING (OGM) ARE MORE PREDICTIVE OF PROGNOSIS THAN THOSE DETECTED BY FISH IN NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Anna Moreno, 4208465

EFFICACY AND SAFETY OF ABECMA® CAR T-CELL THERAPY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS AGED ≥75 YEARS: REAL-WORLD DATA FROM THE FRENCH DESCAR-T REGISTRY

EHA Library, Jihane HSSEIN, 4208469

DIAGNOSTIC VALUE OF TONGUE BIOPSY IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS

EHA Library, Yuping Zhong, 4208478

RENAL RECOVERY AND DEPTH OF RESPONSE WITH DARATUMUMAB-BASED QUADRUPLET VERSUS TRIPLET INDUCTION THERAPY IN TRANSPLANT-ELIGIBLE NDMM WITH RENAL IMPAIRMENT: A MULTICENTER KMMWP2309 STUDY

EHA Library, Ji Hyun Lee, 4208480

WHOLE-BODY DIFFUSION-WEIGHTED MRI VERSUS FDG PET/CT IN MULTIPLE MYELOMA: A PRISMA-BASED SYSTEMATIC REVIEW HIGHLIGHTING DISEASE STAGING AND CLINICAL VALUE IN GLOBAL HEMATOLOGY AND LOW-RESOURCE SETTINGS

EHA Library, KALYSTA BORGES, 4208481

EFFICACY AND SAFETY OF IXAZOMIB PLUS REDUCED-DOSE LENALIDOMIDE VERSUS IXAZOMIB MONOTHERAPY AS MAINTENANCE IN HIGH‑RISK NEWLY DIAGNOSED MULTIPLE MYELOMA: AN INTERIM ANALYSIS OF A PROSPECTIVE STUDY

EHA Library, Xuzhao Zhang, 4208482

PROGNOSTIC VALUE OF MINIMAL RESIDUAL DISEASE STATUS FOR SURVIVAL OUTCOMES IN TRANSPLANT-ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: A META-ANALYSIS

EHA Library, Hira Mian, 4208483

PROGRESSION OF DISEASE WITHIN 24 MONTHS (POD24) IS AN INDEPENDENT PROGNOSTIC FACTOR FOR SURVIVAL IN NEWLY DIAGNOSED PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA TREATED WITH DRC

EHA Library, Maria Gavriatopoulou, 4208485

DUFFY NULL GENOTYPE MODIFIES TREATMENT OUTCOMES IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): EVIDENCE FROM THE COMMPASS STUDY

EHA Library, Chaitanya Acharya, 4208486

GAPS IN ACCESS TO CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY POST LEUKAPHERESIS: WAITING TIME AND TREATMENT PATTERNS IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: REAL‑WORLD EVIDENCE FROM US CLAIMS

EHA Library, John Hartman, 4208488

DEVELOPMENT AND PRELIMINARY CONTENT VALIDATION OF THE PROSIM‑Q: A PATIENT‑REPORTED OCULAR SYMPTOM AND IMPACT QUESTIONNAIRE FOR ONCOLOGY TRIALS

EHA Library, Farrah Pompilus, 4208489

SUSTAINED MRD WITH OR WITHOUT ASCT IN THE ERA OF NEW REGIMENS FOR MULTIPLE MYELOMA: A SYSTEMATIC REVIEW AND NETWORK ANALYSIS

EHA Library, Marco Rossi, 4208490

GENOMIC PROFILING UNVEILS ACTIONABLE VULNERABILITIES AND CLONAL EVOLUTION IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Yajing Zhang, 4208389

CHROMOANAGENESIS DETECTED BY OPTICAL GENOMIC MAPPING PREDICTS ADVERSE OUTCOMES IN MULTIPLE MYELOMA

EHA Library, Charan Vegivinti, 4208393

POLB 001, AN ORAL P38 MAPK INHIBITOR FOR THE PREVENTION OF CYTOKINE RELEASE SYNDROME

EHA Library, Rakesh Popat, 4208397

MONOCLONAL LIGHT CHAIN N-GLYCOSYLATION IS A RISK FACTOR FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PROGRESSION

EHA Library, Min Yang, 4208398

UROLITHIN A AS A DUAL-ACTION ENHANCER OF CAR-T THERAPY  IN MULTIPLE MYELOMA

EHA Library, Raquel Ancos-Pintado, 4208400

SINGLE-CELL PROTEIN AND TRANSCRIPT PROFILING OF BONE MARROW IDENTIFIES IMMUNE FEATURES ASSOCIATED WITH RESPONSE AND PROGRESSION FOLLOWING TALQUETAMAB IN MULTIPLE MYELOMA.

EHA Library, Selma Bekri, 4208401

APOBEC3B COUPLES MITOCHONDRIAL RESPIRATORY ADAPTATION AND INFLAMMATORY REMODELLING IN MULTIPLE MYELOMA

EHA Library, Faezeh Borzooee, 4208402

CD38 EXPRESSION IN PARASKELETAL AND EXTRAMEDULLARY PLASMACYTOMAS IN MULTIPLE MYELOMA: ASSESSMENT IN RELATION TO ANTI-CD38 THERAPY

EHA Library, Martin Stork, 4208404

PERIPHERAL BLOOD IMMUNOPROFILING DEFINES THREE DISTINCT IMMUNE STATES ASSOCIATED WITH CLINICAL AND MOLECULAR AXES IN MULTIPLE MYELOMA

EHA Library, Anastasia Radko, 4208405

NEUTROPHIL DYNAMICS AND NEUTROPHIL EXTRACELLULAR TRAPS (NETS) IN MULTIPLE MYELOMA

EHA Library, Alessandra Romano, 4208406

THE NOVEL INDIRUBIN DERIVATIVE I3MV-8B AUGMENTS ANTI-CD38 MONOCLONAL ANTIBODY THERAPY IN MULTIPLE MYELOMA: A DUAL MECHANISM INVOLVING NK CELL IMMUNOMODULATION AND INCREASED CD38 EXPRESSION

EHA Library, Xiaoyu Zhang, 4208409

REVERTING OF MICROENVIRONMENTAL INVASIVENESS AND IMMUNESUPPRESSION THROUGH A NOVEL ANTI-CD138 ANTIBODY NANOPLATFORM FOR TARGETING OF MULTIPLE MYELOMA

EHA Library, Carmela Tangredi, 4208410

FCΓRIIIA GENOTYPE IN MULTIPLE MYELOMA AND ITS PRECURSORS IS ASSOCIATED WITH BONE DISEASE EXTENSION, ADVERSE CLINICAL PRESENTATION AND IMMUNE DYSFUNCTION

EHA Library, Alessandra Romano, 4208411

EXPLORING THE EPIGENETIC ROLE OF PRDM1: A TARGET FOR IMID-RESISTANT MULTIPLE MYELOMA?

EHA Library, Sophie Ball, 4208412

NON-RELAPSE MORTALITY AFTER CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: AN IFM STUDY FROM THE DESCAR-T REGISTRY

EHA Library, Jeanne LOISEAU, 4208415

DISTINCT MUTATIONAL NETWORK ARCHITECTURE DRIVES RACIAL GENOMIC DISPARITIES IN MULTIPLE MYELOMA RATHER THAN INDIVIDUAL MUTATIONS

EHA Library, Amin Turki, 4208418

REALITEC-2 SUBGROUP ANALYSIS: AN INTERNATIONAL OBSERVATIONAL RETROSPECTIVE STUDY OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA IN THE REAL-WORLD

EHA Library, K Martin Kortum, 4208419

NEW IMS/IMWG RISK CRITERIA BY NEXT-GENERATION SEQUENCING: ANALYSIS OF DARATUMUMAB BENEFIT IN BOTH HIGH- AND STANDARD-RISK PATIENTS IN THE PERSEUS STUDY

EHA Library, Luca Bertamini, 4208420

DE-ESCALATED DOSING OF BELANTAMAB MAFODOTIN PLUS VD REDUCES THE INCIDENCE OF OCULAR EVENTS WHILE MAINTAINING EFFICACY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: A CZECH MULTICENTER PHASE 2 STUDY

EHA Library, Tereza Popková, 4208421

REAL-WORLD BISPECIFIC ANTIBODIES IN MULTIPLE MYELOMA IN THE NETHERLANDS (T-REX): DOSING INTERVALS, INFECTION RISK AND QUALITY OF LIFE.

EHA Library, Marjolein Appelman, 4208422

SERIAL CIRCULATING TUMOR PLASMA CELL MONITORING DYNAMICALLY STRATIFIES PROGRESSION RISK IN A SCREENED SMOLDERING MULTIPLE MYELOMA COHORT

EHA Library, Sigrún Thorsteinsdóttir, 4208423

INTERIM REPORT OF PHASE I RESULTS OF A PHASE I/II, OPEN LABEL STUDY TO EVALUATE SAFETY, TOLERABILITY, AND EFFICACY OF ELRANATAMAB IN PATIENTS WITH RELAPSED AL AMYLOIDOSIS

EHA Library, Giada Bianchi, 4208425

CIBMTR REAL-WORLD OUTCOMES OF FRAIL PATIENTS TREATED WITH IDECABTAGENE VICLEUCEL

EHA Library, Omar Nadeem, 4208427

BELANTAMAB MAFODOTIN, POMALIDOMIDE, AND DEXAMETHASONE (BPD) DEMONSTRATED IMPROVED OUTCOMES AS SECOND-LINE THERAPY VS POMALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE (PVD) IN PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Meral Beksaç, 4208428

A REAL-WORLD STAGING SYSTEM FOR MYELOMA INTEGRATING AGE, PS, RENAL FUNCTION AND THE NEW HIGH-RISK IMS/IMWG SYSTEM OUTPERFORMS EXISTING MODELS: A MACHINE LEARNING STUDY BY THE GREEK MYELOMA STUDY GROUP

EHA Library, Eirini Katodritou, 4208430

REAL-WORLD OUTCOMES OF ZEVORCABTAGENE AUTOLEUCEL, A FULLY HUMAN BCMA-TARGETED CAR-T THERAPY, IN 136 PATIENTS WITH MULTIPLE MYELOMA (MM): A MULTICENTER EXPERIENCE FROM CHINA

EHA Library, Wanyan Ouyang, 4208431

OBESITY IS AN INDEPENDENT AND MODIFIABLE RISK FACTOR FOR MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE AND ITS PROGRESSION TO MULTIPLE MYELOMA: A PROSPECTIVE POPULATION-BASED SCREENING STUDY

EHA Library, Sæmundur Rögnvaldsson, 4208436

REAL-WORLD TREATMENT PATTERNS AND SEQUENCING OF BCMA-TARGETED THERAPIES IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: A GLOBAL MULTI-CENTER ANALYSIS

EHA Library, Nicolas Blin, 4208439

APHERESIS CD4/CD8 RATIO PREDICTS MOVEMENT AND NEUROCOGNITIVE TOXICITY (MNT) AFTER BCMA CAR-T CELL THERAPY IN MULTIPLE MYELOMA

EHA Library, Theresia Akhlaghi, 4208440

MITIGATING THE SEVERITY OF CILTA-CEL ASSOCIATED DELAYED NEUROTOXICITY: A COMPARATIVE ANALYSIS OF PROPHYLACTIC CYCLOPHOSPHAMIDE VERSUS DEXAMETHASONE IN HIGH-EXPANSION PATIENTS

EHA Library, Christoph Schaefers, 4208441

FIRST INDEPENDENT REAL-WORLD EVIDENCE FROM TWO NATIONWIDE COMPASSIONATE-USE PROGRAMS FOR BELANTAMAB MAFODOTIN-BASED COMBINATION THERAPY IN MULTIPLE MYELOMA

EHA Library, Johannes Waldschmidt, 4208442

PHASE 2 STUDY OF APONERMIN + BISPECIFIC ANTIBODIES IN PATIENTS(PTS) WITH RELAPSED/REFRACTORY MULTIPLE : A PROSPECTIVE SINGLE-ARM STUDY

EHA Library, Aijun Liu, 4208444

RISKFACTORS OF INFECTIONS IN TRANPLANT-INELIGBLE MULTIPLE MYELOMA PATIENTS.  A  POPULATION-BASED STUDY ON 6,456 PATIENTS DIAGNOSED 2008-2021  FROM THE SWEDISH MYELOMA REGISTRY

EHA Library, Cecilie Hveding Blimark, 4208445

ELRANATAMAB IN COMBINATION WITH CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: RESULTS FROM THE PHASE 1B MAGNETISMM-20 TRIAL

EHA Library, C. Ola Landgren, 4208447

LOW-DOSE VENETOCLAX PLUS WEEKLY DEXAMETHASONE IN T(11;14)-POSITIVE RELAPSED/REFRACTORY MULTIPLE MYELOMA: FINAL EFFICACY AND SAFETY RESULTS FROM THE PHASE II VICTORIA STUDY

EHA Library, Astrid Hundebøll Torpe, 4208449

EVALUATION OF EARLY M-PROTEIN KINETICS POST-CAR T CELL THERAPY WITH CLONOTYPIC MASS SPECTROMETRY AND COMPARISON WITH BONE MARROW-BASED MEASURABLE RESIDUAL DISEASE.

EHA Library, Ravi Vij, 4208455

IMPACT OF BASELINE BONE MARROW IMMUNE CELL SUBSETS ON OUTCOMES IN MULTIPLE MYELOMA TREATED WITH DARATUMUMAB

EHA Library, Chunrui Li, 4208457

TWO STAGE AI UNMASKS IMMUNE DRIVEN FUNCTIONAL HIGH-RISK IN CYTOGENETIC STANDARD RISK MYELOMA: GUIDING DARATUMUMAB AND ASCT THERAPY

EHA Library, C. Ola Landgren, 4208458

BLEEDING EVENTS IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH BCMA-DIRECTED CAR T-CELLTHERAPY: A SYSTEMATIC REVIEW OF CLINICAL TRIALS

EHA Library, Pedro Henrique Fernandes do Carmo Las Casas, 4208460

DYNAMIC MONITORING OF CIRCULATING PLASMA CELLS IN NEWLY DIAGNOSED MULTIPLE MYELOMA: UPDATED RESULTS FROM A PROSPECTIVE MULTICENTER STUDY IN CHINA

EHA Library, Qun Li, 4208461

ETENTAMIG IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WITH PRIOR EXPOSURE TO B-CELL MATURATION ANTIGEN (BCMA)-TARGETED THERAPY

EHA Library, Saurabh Chhabra, 4208464

STAGE-ADAPTED TREATMENT STRATEGY IN NON-AMYLOID MONOCLONAL GAMMOPATHY OF RENAL SIGNIFICANCE: A REAL-WORLD COHORT ANALYSIS

EHA Library, Junling Zhuang, 4208466

SEX DIFFERENCES IN PROGRESSION TO MALIGNANCY FROM MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE

EHA Library, Ingigerdur Sverrisdottir, 4208467

REAL-WORLD TREATMENT SEQUENCING AFTER CAR-T VS BISPECIFIC ANTIBODIES IN MULTIPLE MYELOMA: NEXT-LINE PATTERNS AND TIME-TO-NEXT-LINE INITIATION IN THE HEALTHTREE REGISTRY

EHA Library, Jorge Arturo Hurtado Martinez, 4208468

OUTPATIENT STEP-UP DOSING OF TECLISTAMAB OR TALQUETAMAB WITH PROPHYLACTIC TOCILIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: REAL-WORLD EVIDENCE FROM A LARGE US CANCER CENTER

EHA Library, Cesar Rodriguez, 4208470

REAL-WORLD OUTCOMES IN SMOLDERING MULTIPLE MYELOMA IN EUROPE: FIRST RESULTS FROM THE SPARK STUDY

EHA Library, María-Victoria Mateos, 4208471

AI-BASED MODEL FOR IDENTIFICATION FUNCTIONAL HIGH-RISK MULTIPLE MYELOMA

EHA Library, Sonia More', 4208472

THE IMS-IMWG 2025 GENOMIC CLASSIFICATION IDENTIFIES HIGH-RISK MULTIPLE MYELOMA PATIENTS IN THE ERA OF BCMA-DIRECTED CAR-T CELL THERAPY.

EHA Library, Almudena Zaratiegui, 4208473

DOES DOSE FRACTIONATION IMPROVE TOLERABILITY IN AUTOLOGOUS STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA? A PROPENSITY SCORE–MATCHED ANALYSIS

EHA Library, Ceren Uzunoğlu Güren, 4208474

SEQUENTIAL TRANSITION TO ALL-ORAL IRD THERAPY FOLLOWING DARA-BASED INDUCTION IN TRANSPLANT-INELIGIBLE NDMM: DEEPENING RESPONSE AND MRD NEGATIVITY

EHA Library, Xibin Xiao, 4208475

COMPARATIVE ANALYSIS OF SUBCUTANEOUS ISA VRD (ISASOCUT) AND INTRAVENOUS ISA VRD (IMROZ) IN TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA ACROSS AGE GROUPS

EHA Library, Arthur Bobin, 4208476

RENAL OUTCOMES BY PALLADINI STAGE AND RESPONSE CRITERIA IN SYSTEMIC AL AMYLOIDOSIS TREATED WITH FIRST-LINE DARA-CYBORD: REAL-WORLD EXPERIENCE FROM A SINGLE AMYLOIDOSIS REFERRAL CENTER

EHA Library, James Di Palma-Grisi, 4208477

LENALIDOMIDE-BASED THERAPY IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AND RENAL IMPAIRMENT: SAFETY OF HIGHER-THAN-LABEL DOSING FROM THE REST TRIAL

EHA Library, Hedda Berg Monsen, 4208479

OVERALL SURVIVAL OF ANTI-BCMA THERAPIES: INDIRECT COMPARISON OF BELANTAMAB MAFODOTIN/BORTEZOMIB/DEXAMETHASONE (BVD) VS TECLISTAMAB/DARATUMUMAB (TEC-DARA) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, Joshua Richter, 4208484

HYPERDIPLOID MULTIPLE MYELOMA: GENETIC HETEROGENEITY

EHA Library, Anikó Ujfalusi, 4208487